Posts from this topic will be added to your daily email digest and your homepage feed. US billionaire Warren Buffett likes to note how little advantage his considerable wealth secures him over the ...
Biogen Idec announced results from the daclizumab high-yield process (DAC HYP) SELECT clinical trial. DAC HYP, a subcutaneous formulation of daclizumab for the treatment of relapsing-remitting ...
Biogen Idec (NASDAQ: BIIB) and Abbott (NYSE: ABT) today announced positive top-line results from SELECT, a global, registrational Phase 2b clinical trial designed to evaluate the investigational ...
announced that results from the daclizumab high-yield process (DAC HYP) SELECT clinical trial have been published as an online article in The Lancet. SELECT was a Phase 2b study designed to determine ...
Biogen Idec and Abbott announced positive top-line results from SELECT, a global, registrational phase II b clinical trial designed to evaluate the investigational compound daclizumab high-yield ...
WESTON, Mass. & ABBOTT PARK, Ill.--(BUSINESS WIRE)-- Biogen Idec (NASDAQ: BIIB) and Abbott (NYSE: ABT) today announced positive top-line results from SELECT, a global, registrational Phase 2b clinical ...
The iBasso DC03 portable DAC-Amplifier is priced at Rs. 4,999, and promises to serve as a capable bridge between the high-resolution music on your smartphone or computer, and your budget audiophile ...
WESTON, Mass. & ABBOTT PARK, Ill.--(BUSINESS WIRE)-- Biogen Idec (NASDAQ: BIIB) and Abbott (NYSE: ABT) today announced positive top-line results from SELECT, a global, registrational Phase 2b clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback